Galderma launched “We Are All Sculptra”, showcasing Sculptra’s regenerative versatility across diverse patient demographics.
The programme tracks nine treatment-naïve participants over two years. It delivers longitudinal insights into tailoring regenerative biostimulation across ages, skin types, ethnicities, and aesthetic goals. Through structured clinical documentation, standardised imaging, and patient-reported video diaries, the initiative provides real-world evidence of outcomes in routine practice settings.
Focus on sustained regeneration
Unlike short-term aesthetic case studies, “We Are All Sculptra” emphasises sustained tissue regeneration and progressive improvement. Sculptra, formulated with poly-L-lactic acid (PLLA-SCA™), works by stimulating the skin’s natural collagen and elastin production processes. This mechanism supports gradual volumisation, enhanced skin firmness, improved texture, and long-term structural support rather than immediate volumetric correction.
Strengthening regenerative injectables
For healthcare professionals and aesthetic clinics, the initiative underscores the commercial and clinical relevance of regenerative injectables within modern practice. As demand shifts toward natural, long-lasting outcomes, clinicians position biostimulators as core treatments instead of adjunct solutions.
Standardised yet scalable treatment frameworks
The programme also highlights Galderma’s proprietary treatment frameworks, including AART™ (Assessment, Anatomy, Range, and Treatment) and HIT™ (Holistic Individualised Treatment). These protocols enable practitioners to standardise patient assessment while maintaining customisation at scale—a critical balance for multi-location clinics and expanding aesthetic networks seeking consistent outcomes.
According to Galderma’s scientific leadership, regenerative aesthetics represent a structural evolution in the category. These protocols help practitioners standardise assessments while delivering scalable customisation for multi-location clinics seeking consistent outcomes.
From a market standpoint, the initiative reinforces Galderma’s strategy to differentiate through science-led innovation and clinical validation. The company continues to expand evidence-based positioning within the high-growth injectable segment.
Advancing inclusivity in aesthetic medicine
Importantly, “We Are All Sculptra” also addresses inclusivity in aesthetic medicine. The initiative documents outcomes across diverse patient profiles. It strengthens practitioner confidence in applying regenerative protocols across varied skin biology and evolving treatment goals.
For distributors, clinic owners, and aesthetic practitioners, the initiative serves as both an educational resource and a market-development tool. It demonstrates how regenerative biostimulation can drive patient lifetime value through phased treatments, follow-up protocols, and maintenance strategies.
With this campaign, Galderma positions Sculptra as a long-term regenerative platform aligned with evolving patient preferences and evidence-based practice. The initiative signals continued investment in outcome transparency, practitioner education, and scalable personalisation.